Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024

Euro Surveill. 2024 Feb;29(6):2400046. doi: 10.2807/1560-7917.ES.2024.29.6.2400046.ABSTRACTThe monoclonal antibody nirsevimab was at least 70% effective in preventing hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory syncytial virus (RSV) in Spain (Oct 2023-Jan 2024), where a universal immunisation programme began late September (coverage range: 79-99%). High protection was confirmed by two methodological designs (screening and test-negative) in a multicentre active surveillance in nine hospitals in three regions. No protection against RSV-negative LRTI-hospitalisations was shown. These interim results could guide public-health decision-making.PMID:38333937 | PMC:PMC10853977 | DOI:10.2807/1560-7917.ES.2024.29.6.2400046

Source: Euro Surveill - February 9, 2024 Category: Infectious Diseases Authors: M ónica López-Lacort Cintia Mu ñoz-Quiles Ainara Mira-Iglesias F Xavier L ópez-Labrador Beatriz Mengual-Chuli á Carlos Fern ández-García Mario Carballido-Fern ández Ana Pineda-Caplliure Juan Mollar-Maseres Maruan Shalabi Benavent Francisco Sanz-He Source Type: research